Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University Health Network, Toronto
Emory University
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Baylor College of Medicine
St. Jude Children's Research Hospital
University of Southern California
UNICANCER